Stock screenerAll disclosures →
EDGAR →
TCRX
Conviction 0HealthcareScan · Mon, Aug 10, 2026TCRX$0.7718-3.06%
ResistanceSupportVol 14Vol MA14 545.36K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price0.7718
Change-3.06%
Gap-2.03%
Rel volume0.12×
Avg volume549.49K
Avg $ vol454.02K
SMA 200.8213
SMA 500.9185
SMA 2001.08
Price vs 50-15.97%
Price vs 200-28.49%
MA stackbearish
50/200 cross—
Supertrenddown · 0.9502
RSI (14)41
MACD hist0.00
MACD crossbull · 0d
Stoch %K / %D23 / 25
ADX (14)17
+DI / −DI15 / 18
RSI divergence—
MACD divergence—
ATR %+8.58%
ADR %7.53%
52w high2.52
52w low0.7234
From 52w high-69.37%
Above 52w low+6.69%
New 52w highNo
SqueezeOff
Bollinger width37.10%
%B0.34
Donchian pos17.22%
Donchian high1.04
Donchian low0.7160
AVWAP (52w high)1.12
vs AVWAP high-31.04%
AVWAP (52w low)0.7562
vs AVWAP low+2.07%
OBV trendDown
Chaikin MF (20)-0.44
Today vs 20d0.12×
Avg vol (14d)545.36K
Avg vol (20d)549.49K
Avg $ vol (20d)454.02K
Market cap18.51M
RS 3m (vs SPY)-39.90%
RS 6m (vs SPY)-26.66%
RS line new highNo
Trend template0/8
Technical rank11.3
1 week+6.69%
1 month-29.19%
3 months-38.75%
6 months-25.07%
1 year-53.22%
YTD-24.33%
P/E-0.14
P/B0.19
P/S1.79
P/FCF-0.13
EPS-1.00
Div yield—
ROE-133.89%
ROA-64.24%
Debt/Eq0.44
Current6.65
EV/EBITDA0.50
Gross margin—
Net margin—
Rev growth266.65%
EPS growth-1.78%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value-66.56M
Revenue982K
Net income-28.67M
Gross profit—
Free cash flow-139.73M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out61.07M
Employees142
ListedFri, Jul 16, 2021
Free float42.76M
Float %81.5%
Short interest1.38M
Days to cover1.2d
Short volume41.0%
Squeeze score13 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank11.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.20
Support0.7240
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in TCRX
No recent disclosed trades by Congress in TCRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in TCRX · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
BAKER FELIX Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Klencke Barbara Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Nicholson Garry A Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Dorton Katina Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
BAKER BROS. ADVISORS LP Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Baker Brothers Life Sciences LP Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
667, L.P. Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
BAKER JULIAN Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Baker Bros. Advisors (GP) LLC Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Woods Keith Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
SEC filings
EDGAR filings in TCRX · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.